跳至主要内容
临床试验/JPRN-UMIN000000619
JPRN-UMIN000000619已完成1 期

Phase I clinical trial of pan-HLA type personalized peptide vaccine for advanced cancer patients - Pan-HLA type personalized peptide vaccine trial for cancer patients

Department of Immunology, Kurume University School of Medicine0 个研究点目标入组 40 人开始时间: 2007年3月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • The following patients must be excluded: 1) Patients are negative for HLA-A2, -A3, -A11, -A24, -A31, and -A33. 2) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation etc). 3) Patients with the past history of severe allergic reactions. 4) Pregnant, nursing, or who wants pregnancy. Patients with no acceptance of use effective contraception during and for at least 70 days after study participation. 5) Patients who are judged inappropriate for the clinical trial by doctors.

研究者

发起方
Department of Immunology, Kurume University School of Medicine

相似试验